Medicine Recommendations

Pagets Disease

Pain

Pain

Dietary management of patients with cystic fibrosis

Depressive illness, post-traumatic stress disorder, obsessive compulsive disorder, panic disorder, social phobia, generalised anxiety disorder

For treating hyperkalaemia (TA 623)

Age-related macular degeneration (NICE TA155)

NICE TA 155 - Ranibizumab and pegaptanib for the treatment of age-related macular degeneration

All indications

Rheumatic diseases

​​**Please note - For Blackpool and Fylde & Wyre CCG DMARD Shared Care Guidelines please use the versions available on the CCG website 

Pentosan Polysulfate Sodium for treating bladder pain (NICE TA610)

Peripheral arterial disease (NICE TA223)

NICE TA223 - Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease 

Partial-onset seizures with or without secondary generalised seizures

MHRA Drug Safety Update - Antiepileptic drugs: updated advice on switching between different manufacturers’ products   

Schizophrenia and other psychoses, short term management of severe anxiety, psychomotor agitation, violent or dangerously impulsive behaviour

Heart failure, hypertension, diabetic nephropathy and prophylaxis of cardiovascular events

Schizophrenia and other psychoses, mania, short term management of severe anxiety, psychomotor agitation, violent or dangerously impulsive behaviour

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Depressive illness

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.

Hypertensive episodes in phaeochromocytoma

Topical treatment for atopic eczema (NICE TA 82)

NICE TA82 - Tacrolimus and pimecrolimus for atopic eczema 

Psoriasis

Schizophrenia, monosymptomatic hypochondriacal psychosis, paranoid psychosis

The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.